

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: BRAJLHRHAI

d previous ble se inhibitor tabletstablets	and ONE L	.HRH ag		gy & Alert Form
tablets	Repeat x _		jonist	
tablets	Repeat x _		onist	
	_			
tablets	Demost v			
tablets	Donast v			
	Repeat x			
tablets	Repeat x			
userelin long acting (SUPREFACT DEPOT) 6.3 mg subcutaneous even			eeks x	treatments
	9.45 mg subcutaneous every 12 weeks xt			
		-		
☐ 3.6 mg	subcutaneous	every 4 w	eeks x	treatments
☐ 10.8 mg	g subcutaneou	s every 12	weeks x	treatments
7.5 mg IM every 4 weeks xtreatments				
☐ 22.5 mg	J IM every 12 w	eeks x	treat	tments
I APPOINT	MENT OR	DERS		
☐ trialvcerides	☐ bone dens	sitv		
		,		
equests.				
DOCTOR'S SIGNATURE:			SIGNATURE:	
	☐ 6.3 mg ☐ 9.45 mg ☐ 3.6 mg ☐ 10.8 mg ☐ 7.5 mg ☐ 22.5 mg ☐ triglycerides	☐ 6.3 mg subcutaneous ☐ 9.45 mg subcutaneous ☐ 3.6 mg subcutaneous ☐ 10.8 mg subcutaneous ☐ 7.5 mg IM every 4 wee ☐ 22.5 mg IM every 12 w	□ 9.45 mg subcutaneous every 12 □ 3.6 mg subcutaneous every 4 w □ 10.8 mg subcutaneous every 12 □ 7.5 mg IM every 4 weeks x □ 22.5 mg IM every 12 weeks x □ triglycerides □ bone density	☐ 6.3 mg subcutaneous every 8 weeks x